Scarica l'app Stockscreener
754.99
1.90%
13.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$741.29
Aprire:
$748.85
Volume 24 ore:
534.08K
Relative Volume:
0.50
Capitalizzazione di mercato:
$79.34B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
18.07
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
+7.41%
1M Prestazione:
+8.92%
6M Prestazione:
+42.73%
1 anno Prestazione:
+3.29%
Intervallo 1D:
$746.38
$756.67
Intervallo di 1 settimana:
$691.86
$756.67
Portata 52W:
$476.49
$790.98
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
754.88 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.50 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
846.59 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.05 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.50 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera - Yahoo Finance
MASTERINVEST Kapitalanlage GmbH Makes New $1.14 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bayer-Regeneron Aflibercept 8 mg recommended for EU approval for third retinal indication - Medical Dialogues
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow - sharewise.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $768.00 Price Target at Morgan Stanley - MarketBeat
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow - The Motley Fool
The Manufacturers Life Insurance Company Has $199.26 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Game Creek Capital LP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bellevue Group AG Sells 1,779 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Regeneron Pharmaceuticals (REGN) Receives Updated Analyst Ratings from Morgan Stanley | REGN Stock News - GuruFocus
Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Paroxysmal Nocturnal Hemoglobinuria Market to Experience - openPR.com
Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $768 From $767, Maintains Equalweight Rating - marketscreener.com
WINTON GROUP Ltd Invests $710,000 in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Armistice Capital LLC - MarketBeat
Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals - MSN
Intact Investment Management Inc. Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How Investors May Respond To Regeneron (REGN) Lynozyfic Multiple Myeloma Data And Frontline Oncology Ambitions - simplywall.st
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial - whbl.com
Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock? - MSN
Wells Fargo & Company Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Wells Fargo Raises Price Target for Regeneron (REGN) to $745 | REGN Stock News - GuruFocus
How Is The Market Feeling About Regeneron Pharmaceuticals Inc? - Benzinga
Transcript : Regeneron Pharmaceuticals, Inc.Special Call - marketscreener.com
Regeneron (REGN): Revisiting Valuation After Recent Pullback and 90-Day Share Price Surge - Yahoo Finance
Stempoint Capital LP Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $745 From $700, Maintains Equalweight Rating - marketscreener.com
iSAM Funds UK Ltd Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
State Street Corp Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diadema Partners LP Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Axa S.A. Sells 20,836 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery - BioSpace
Regeneron (REGN): Revisiting Valuation After a Short-Term Pullback and Longer-Term Shareholder Weakness - simplywall.st
Kymera Keeps Rising With More Positive Dupixent-In-A-Pill Data - Citeline News & Insights
Regeneron Pharmaceuticals' Upcoming Melanoma Data Likely to Look Competitive, RBC Says - marketscreener.com
ASH takeaways: Regeneron unveils new data on blood cancer drugs, touts hematology pipeline - Medical Marketing and Media
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MSN
Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now - TradingView
Ossiam Sells 22,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Stock Slides 11% With A 8-Day Losing Spree - Trefis
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention (NASDAQ:REGN) - Seeking Alpha
Regeneron's (REGN) Recovery and Dupixent Strength Support BMO's Outperform Rating - Finviz
Regeneron’s (REGN) recovery and Dupixent strength support BMO’s outperform rating - MSN
Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating - Insider Monkey
Why Is Kymera Therapeutics Stock Skyrocketing Monday?Kymera Therapeutics (NASDAQ:KYMR) - Benzinga
Natixis Purchases 2,751 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Anti-VEGF Market Growth Outlook: USD 41.3 Billion by 2035 With - openPR.com
California Public Employees Retirement System Sells 158,734 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bank of Nova Scotia Purchases 126,689 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
14 Best US Stocks to Buy for Long Term - Insider Monkey
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.96%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):